title: Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation.
abstract: Hereditary C2 deficiency (C2D) is an important susceptibility factor for invasive infections caused by encapsulated bacteria such as pneumococci and Haemophilus influenzae type b. The infections are mostly seen in childhood indicating that antibody-mediated acquired immunity is affected. C2D persons and healthy controls were vaccinated with ActHIB® and Pneumo23®. Analysis of specific antibodies to pneumococci serotype 6B, 7F, and 23F, and Hib was performed. Post-vaccination IgG antibodies against pneumococci serotype 6B and 23F at a concentration ≥1.0mg/L was found in similar frequency in C2D persons and controls. Post-vaccination sera from C2D persons showed poor complement-mediated opsonization and phagocytosis of pneumococci by granulocytes when depending on classical and lectin pathway activation only, but increased (p=0.007) and equaled that of the normal controls when also alternative pathway activation was allowed due to antibody-dependent C2 bypass activation. In conclusion, the C2D persons benefited from the vaccination and achieve an increased phagocytic capacity.
authors: Department of Infectious Diseases Skåne University Hospital, Lund, Sweden. goran.b.jonsson@skane.se
authors: Göran
authors: G
authors: Jönsson
authors: Christian
authors: C
authors: Lood
authors: Birgitta
authors: B
authors: Gullstrand
authors: Eva
authors: E
authors: Holmström
authors: Barbro
authors: B
authors: Selander
authors: Jean Henrik
authors: JH
authors: Braconier
authors: Gunnar
authors: G
authors: Sturfelt
authors: Anders A
authors: AA
authors: Bengtsson
authors: Lennart
authors: L
authors: Truedsson
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000917:Antibody Formation; D001428:Bacterial Vaccines / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003167:Complement Activation / Q000276:immunology*; D003175:Complement C2 / Q000172:deficiency* / Q000276:immunology*; D003170:Complement Pathway, Alternative / Q000276:immunology; D003171:Complement Pathway, Classical / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006098:Granulocytes / Q000276:immunology; D006192:Haemophilus Infections / Q000276:immunology; D019741:Haemophilus influenzae type b / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009895:Opsonin Proteins / Q000276:immunology*; D010587:Phagocytosis / Q000276:immunology; D011008:Pneumococcal Infections / Q000276:immunology; D012756:Sheep; D013296:Streptococcus pneumoniae / Q000276:immunology; D014611:Vaccination / Q000379:methods; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D003175:Complement C2; D007074:Immunoglobulin G; D009895:Opsonin Proteins